Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immu...
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTDLow-dose IL-2 plus CTLA-4 Ig has previously demonstrated restoration of regulatory T-cell function together with reduction of inflammatory cytokines and monocyte activation in treated patientsFindings of this biomarker study are consistent with previously reported results of an Investigator-Initiated-Trial of LD IL-2 and CTLA-4 Ig in patients with FTD HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (F
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics (COYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics (COYA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial ResultsBusiness Wire
- Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
- Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial [Yahoo! Finance]Yahoo! Finance
COYA
Earnings
- 3/16/26 - Miss
COYA
Sec Filings
- 3/20/26 - Form 424B3
- 3/16/26 - Form S-3
- 3/16/26 - Form 10-K
- COYA's page on the SEC website